Dimerix limited (DXB)

[SCHUMACHER]

http://dimerix.com/
BOUGHT A FEW OF THESE TODAY as i like the story and their fast track approach - Bought at 1.3c - Currently at Phase 11 trials and had some successes to date read on... some good volume of late leading into trial results

http://www.aspectfinancial.com.au/do...A==&popup=true

http://www.aspectfinancial.com.au/do...A==&popup=true

http://www.aspectfinancial.com.au/do...A==&popup=true

Dimerix announces outcomes of DMX-200 pre-IND meeting with the FDA

KEY POINTS:

 Path to drug registration in USA of DMX-200 in patients with chronic kidney disease (CKD)confirmed

 Path to the near term milestone of filing IND for the first US study(PK study) –no apparent road blocks or
extra costs identified at this stage

 DMX-200 to be treated as an adjunct therapy rather than a combination therapy–resultingin a much smaller
pivotal trial which is less expensive as it requires fewer patients

 Potential for approval from asingle pivotal Phase IIItrialwith single end point of improvement in proteinuria
from baseline
–bringing huge cost benefits over running two

Phase III trials
 Recognition of the importance of heterodimer pharmacology– validating the patented Dimerix technology in identifying new treatments


Who we are:
A clinical
-stage drug development company focused on commercialising new therapeutic treatments identified using our proprietary drug discovery platform.
Discovery Platform:
Receptor-HIT technology to identify clinical opportunities from drug-receptor interactions, and potential revenue generation.

Lead Program:
A therapy (DMX-200) currently in Phase II clinical trial for Chronic Kidney Disease (CKD) and US Orphan Drug Designation for Focal Segmental
Glomerulosclerosis (FSGS).

Leadership:
Commercially focused and experienced board and management with a record of hitting milestones and creating significant shareholder value.
Key Assets 3
•Pre IND meeting with FDA held 29th June 2016
•Therapeutic use patent granted in USA 19th April 2016